Literature DB >> 24833769

Polypharmacy in patients hospitalised for acute exacerbation of COPD.

Jesús Díez-Manglano1, José Barquero-Romero2, Pedro Almagro Mena3, Jesús Recio-Iglesias4, Javier Cabrera-Aguilar5, Francisco López-García6, Ramón Boixeda Viu7, Joan B Soriano8.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24833769     DOI： 10.1183/09031936.00014814

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

Review 1.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

2.  Excessive polypharmacy and survival in polypathological patients.

Authors:  Jesús Díez-Manglano; Mercedes Giménez-López; Vanesa Garcés-Horna; María Sevil-Puras; Elena Castellar-Otín; Paloma González-García; Isabel Fiteni-Mera; Teresa Morlanes-Navarro
Journal:  Eur J Clin Pharmacol       Date:  2015-04-26       Impact factor: 2.953

3.  Diseases Linked to Polypharmacy in Elderly Patients.

Authors:  Ioannis Vrettos; Panagiota Voukelatou; Apostolos Katsoras; Despoina Theotoka; Andreas Kalliakmanis
Journal:  Curr Gerontol Geriatr Res       Date:  2017-12-25

4.  When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.

Authors:  S Gaduzo; V McGovern; J Roberts; J E Scullion; D Singh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-13

5.  Managing multimorbidity in primary care in patients with chronic respiratory conditions.

Authors:  Deborah Morrison; Karolina Agur; Stewart Mercer; Andreia Eiras; Juan I González-Montalvo; Kevin Gruffydd-Jones
Journal:  NPJ Prim Care Respir Med       Date:  2016-09-15       Impact factor: 2.871

6.  Examining patterns of multimorbidity, polypharmacy and risk of adverse drug reactions in chronic obstructive pulmonary disease: a cross-sectional UK Biobank study.

Authors:  Peter Hanlon; Barbara I Nicholl; Bhautesh Dinesh Jani; Ross McQueenie; Duncan Lee; Katie I Gallacher; Frances S Mair
Journal:  BMJ Open       Date:  2018-01-14       Impact factor: 2.692

7.  Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD.

Authors:  Netsanet A Negewo; Peter G Gibson; Peter Ab Wark; Jodie L Simpson; Vanessa M McDonald
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-06

8.  A non-randomised controlled pilot study of clinical pharmacist collaborative intervention for community dwelling patients with COPD.

Authors:  Vicki Hunt; Dave Anderson; Richard Lowrie; Colette Montgomery Sardar; Susan Ballantyne; Graeme Bryson; John Kyle; Peter Hanlon
Journal:  NPJ Prim Care Respir Med       Date:  2018-10-10       Impact factor: 2.871
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.